GDF15: a Potential Therapeutic Target for Type 1 Diabetes

Overview

Journal Expert Opin Ther Targets

Publisher Informa Healthcare

Specialty Pharmacology

Date 2022 Feb 9

PMID 35138971

Authors

Soumyadeep Sarkar

John T Melchior

Hayden R Henry

Farooq Syed

Raghavendra G Mirmira

Ernesto S Nakayasu

Thomas O Metz

Affiliations

Soon will be listed here.

Abstract

Introduction: Current treatment for type 1 diabetes (T1D) is centered around insulin supplementation to manage the effects of pancreatic β cell loss. GDF15 is a potential preventative therapy against T1D progression that could work to curb increasing disease incidence.

Areas Covered: This paper discusses the known actions of GDF15, a pleiotropic protein with metabolic, feeding, and immunomodulatory effects, connecting them to highlight the open opportunities for future research. The role of GDF15 in the prevention of insulitis and protection of pancreatic β cells against pro-inflammatory cytokine-mediated cellular stress are examined and the pharmacological promise of GDF15 and critical areas of future research are discussed.

Expert Opinion: GDF15 shows promise as a potential intervention but requires further development. Preclinical studies have shown poor efficacy, but this result may be confounded by the measurement of gross GDF15 instead of the active form. Additionally, the effect of GDF15 in the induction of anorexia and nausea-like behavior and short-half-life present significant challenges to its deployment, but a systems pharmacology approach paired with chronotherapy may provide a possible solution to therapy for this currently unpreventable disease.

Citing Articles

GDF-15 and mtDNA Deletions Are Useful Biomarkers of Mitochondrial Dysfunction in Insulin Resistance and PCOS.

Varhegyi V, Modos A, Trager D, Gerszi D, Horvath E, Sipos M Int J Mol Sci. 2024; 25(20).

PMID: 39456699 PMC: 11507876. DOI: 10.3390/ijms252010916.

Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.

Hoekx C, Straat M, Bizino M, van Eyk H, Lamb H, Smit J Exp Physiol. 2024; 109(8):1292-1304.

PMID: 38965822 PMC: 11291866. DOI: 10.1113/EP091815.

Growth differentiation factor 15 (GDF-15) in endocrinology.

Iglesias P, Silvestre R, Diez J Endocrine. 2023; 81(3):419-431.

PMID: 37129758 DOI: 10.1007/s12020-023-03377-9.

Overview of growth differentiation factor 15 in metabolic syndrome.

Asrih M, Wei S, Nguyen T, Yi H, Ryu D, Gariani K J Cell Mol Med. 2023; 27(9):1157-1167.

PMID: 36992609 PMC: 10148061. DOI: 10.1111/jcmm.17725.

plays a critical role in insulin secretion in INS-1 cells and human pancreatic islets.

Mohammad M, Saeed R, Mohammed A, Khalique A, Hamad M, El-Huneidi W Exp Biol Med (Maywood). 2023; 248(4):339-349.

PMID: 36740767 PMC: 10159522. DOI: 10.1177/15353702221146552.

References

Vila G, Riedl M, Anderwald C, Resl M, Handisurya A, Clodi M . The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem. 2010; 57(2):309-16. DOI: 10.1373/clinchem.2010.153726. View

Couper J, Haller M, Greenbaum C, Ziegler A, Wherrett D, Knip M . ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes. 2018; 19 Suppl 27:20-27. DOI: 10.1111/pedi.12734. View

Aguilar-Recarte D, Barroso E, Guma A, Pizarro-Delgado J, Pena L, Ruart M . GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK. Cell Rep. 2021; 36(6):109501. DOI: 10.1016/j.celrep.2021.109501. View

Sivitz W, Yorek M . Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal. 2009; 12(4):537-77. PMC: 2824521. DOI: 10.1089/ars.2009.2531. View

Fejzo M, Arzy D, Tian R, MacGibbon K, Mullin P . Evidence GDF15 Plays a Role in Familial and Recurrent Hyperemesis Gravidarum. Geburtshilfe Frauenheilkd. 2018; 78(9):866-870. PMC: 6138473. DOI: 10.1055/a-0661-0287. View

Brown D, Lindmark F, Stattin P, Balter K, Adami H, Zheng S . Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res. 2009; 15(21):6658-64. PMC: 3557964. DOI: 10.1158/1078-0432.CCR-08-3126. View

Lockhart S, ORahilly S . Colchicine-an old dog with new tricks. Nat Metab. 2021; 3(4):451-452. DOI: 10.1038/s42255-021-00360-4. View

Myhre P, Prebensen C, Strand H, Roysland R, Jonassen C, Rangberg A . Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19. Circulation. 2020; 142(22):2128-2137. PMC: 7688084. DOI: 10.1161/CIRCULATIONAHA.120.050360. View

Dallmann R, Brown S, Gachon F . Chronopharmacology: new insights and therapeutic implications. Annu Rev Pharmacol Toxicol. 2013; 54:339-61. PMC: 3885389. DOI: 10.1146/annurev-pharmtox-011613-135923. View

10.

Moore A, Brown D, Fairlie W, Bauskin A, Brown P, Munier M . The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab. 2001; 85(12):4781-8. DOI: 10.1210/jcem.85.12.7007. View

11.

Berg A, Lin Y, Lisanti M, Scherer P . Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am J Physiol Endocrinol Metab. 2004; 287(6):E1178-88. DOI: 10.1152/ajpendo.00002.2004. View

12.

Paralkar V, Vail A, Grasser W, Brown T, Xu H, Vukicevic S . Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem. 1998; 273(22):13760-7. DOI: 10.1074/jbc.273.22.13760. View

13.

Dotta F, Censini S, van Halteren A, Marselli L, Masini M, Dionisi S . Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A. 2007; 104(12):5115-20. PMC: 1829272. DOI: 10.1073/pnas.0700442104. View

14.

Eisenbarth G . Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986; 314(21):1360-8. DOI: 10.1056/NEJM198605223142106. View

15.

Wischhusen J, Melero I, Fridman W . Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020; 11:951. PMC: 7248355. DOI: 10.3389/fimmu.2020.00951. View

16.

Bauskin A, Brown D, Junankar S, Rasiah K, Eggleton S, Hunter M . The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res. 2005; 65(6):2330-6. DOI: 10.1158/0008-5472.CAN-04-3827. View

17.

Li D, Zhang H, Zhong Y . Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice. Biochem Biophys Res Commun. 2017; 498(3):388-394. DOI: 10.1016/j.bbrc.2017.08.096. View

18.

Eling T, Baek S, Shim M, Lee C . NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol. 2006; 39(6):649-55. DOI: 10.5483/bmbrep.2006.39.6.649. View

19.

Li C, Wang J, Kong J, Tang J, Wu Y, Xu E . GDF15 promotes EMT and metastasis in colorectal cancer. Oncotarget. 2015; 7(1):860-72. PMC: 4808038. DOI: 10.18632/oncotarget.6205. View

20.

Carrero J, P McCarthy D, Ferris S, Wan X, Hu H, Zinselmeyer B . Resident macrophages of pancreatic islets have a seminal role in the initiation of autoimmune diabetes of NOD mice. Proc Natl Acad Sci U S A. 2017; 114(48):E10418-E10427. PMC: 5715775. DOI: 10.1073/pnas.1713543114. View